Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ALTER-L029

  • participants needed
  • sponsor
    Anhui Shi, MD
Updated on 27 January 2022


Evaluate the efficacy and safety of Anlotinib following concurrent chemoradiation in patients with stage III unresectable non-small cell lung cancer


Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug AdministrationSFDA:2011L00661 which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR1VEGFR2VEGFR3FGFR1/2/3PDGFRa/ c-Kit and MET.

Condition Non Small Cell Lung Cancer Stage III
Treatment Anlotinib
Clinical Study IdentifierNCT03743129
SponsorAnhui Shi, MD
Last Modified on27 January 2022

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note